Baseline characteristics
| Patient characteristics . | N = 152 . |
|---|---|
| Median age, y (range) | 61 (19-90) |
| Female | 72 (47%) |
| Performance status | |
| 0-1 | 93 (82%) |
| ≥2 | 21 (18%) |
| Missing | 38 |
| Clinical disease type | |
| De novo | 120 (79%) |
| Secondary | 27 (18%) |
| Therapy-related | 5 (3.3%) |
| Disease status | |
| Refractory to last line of therapy | 53 (35%) |
| Relapse | 99 (65%) |
| No. of prior lines of therapy (range) | 1-6 |
| 1 | 98 (64%) |
| ≥2 | 54 (36%) |
| Previous therapies | |
| FLT3 inhibitor∗ | 63 (41%) |
| Midostaurin | 58 (38%) |
| Quizartinib | 3 (2.0%) |
| Sorafenib | 7 (4.6%) |
| Intensive chemotherapy | 121 (80%) |
| Venetoclax | 37 (24%) |
| Allogeneic transplant | 29 (19%) |
| Intensity of first-line AML therapy | |
| Intensive chemotherapy (DA, FLAG-Ida or CPX-351) | 117 (77%) |
| Low intensity (azacitidine or LDAC with/without venetoclax) | 35 (23%) |
| Venetoclax with azacitidine or LDAC | 22 (14%) |
| Patient characteristics . | N = 152 . |
|---|---|
| Median age, y (range) | 61 (19-90) |
| Female | 72 (47%) |
| Performance status | |
| 0-1 | 93 (82%) |
| ≥2 | 21 (18%) |
| Missing | 38 |
| Clinical disease type | |
| De novo | 120 (79%) |
| Secondary | 27 (18%) |
| Therapy-related | 5 (3.3%) |
| Disease status | |
| Refractory to last line of therapy | 53 (35%) |
| Relapse | 99 (65%) |
| No. of prior lines of therapy (range) | 1-6 |
| 1 | 98 (64%) |
| ≥2 | 54 (36%) |
| Previous therapies | |
| FLT3 inhibitor∗ | 63 (41%) |
| Midostaurin | 58 (38%) |
| Quizartinib | 3 (2.0%) |
| Sorafenib | 7 (4.6%) |
| Intensive chemotherapy | 121 (80%) |
| Venetoclax | 37 (24%) |
| Allogeneic transplant | 29 (19%) |
| Intensity of first-line AML therapy | |
| Intensive chemotherapy (DA, FLAG-Ida or CPX-351) | 117 (77%) |
| Low intensity (azacitidine or LDAC with/without venetoclax) | 35 (23%) |
| Venetoclax with azacitidine or LDAC | 22 (14%) |
DA, daunorubicin and cytarabine; FLAG-Ida, fludarabine, cytarabine, granulocyte-colony stimulating factor (G-CSF) and idarubicin; LDAC, low-dose cytarabine.
Five patients previously exposed to both midostaurin and sorafenib.